ArticleCureus2025
Improving the Response of High-Grade Glioma (HGG) Cells to Temozolomide Treatment Through Combination With Imatinib.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-grade gliomas (HGGs), the most common adult brain tumors, have always posed a dreaded prognosis to patients and difficulties to medical professionals due to their high heterogeneity and resistance to treatment. In terms of standard of care, maximal surgical resection along with temozolomide (TMZ) and radiotherapy (RT) has remained the current first-line treatment for HGG for decades. Surgical resection has experienced improvements due to neuronavigation and novel imaging sequences, which facilitate a more precise tumor removal while decreasing morbidity. TMZ remains the only approved first-line therapy with limited efficiency, in part because of the developing resistance and side effects. One of the characteristics of HGGs is the presence of multiple receptor tyrosine kinase (RTK) pathways that are aberrantly activated; thus, resistance to treatment as well as uncontrolled proliferation might be attributed in part to these pathways. Our current study aims to evaluate the potential cytotoxic effects of an alkylating cytostatic, TMZ, in combination with a multitarget tyrosine kinase inhibitor (TKI), namely imatinib mesylate (IMT), in comparison to their effects in monotherapy in an in vitro environment.
methodsHGG cells growing in Roswell Park Memorial Institute Medium (RPMI) standard medium were treated with TMZ and IMT in both monotherapy and combined therapy, and the in vitrocytotoxicity was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Drug interaction (I) was classified by the multiplicative method.
resultsIn the in vitro conditions, each drug exhibited cytotoxic effects in monotherapy in a dose-dependent manner. TMZ and IMT combined regimens were synergistic in 31.9%, additive in 31.9%, and subadditive in 36.1% of the combinations.
conclusionsTMZ and IMT demonstrated cytotoxic effects in both monotherapy and combination therapy. Dual therapy yielded predominantly synergistic and additive effects, with subadditive results in approximately one-third of the combinations. Overall, combination therapy produced a better cytotoxic behavior than its individual effects in an in vitro setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.